-
×
Glimepiride 1 mg Tablets - ASORIN 1 Tablets
1 × ₹399.00
Subtotal: ₹399.00
Metformin Hydrochloride Prolonged Release & Glimepiride Tablets IP – ASORIN M1 Tablets
₹850.00
Glimepiride 1 mg + Metformin Hydrochloride Prolonged Release I.P. 500 mg.
Packing – 10*10 BLI
Metformin Hydrochloride Prolonged Release & Glimepiride Tablets IP – A well-rounded approach to manage T2DM with complementary actions.
ASORIN M1 Tablets: The composition of Glimepiride 1 mg + Metformin Hydrochloride Prolonged Release IP 500 mg combines Glimepiride, a sulfonylurea antidiabetic medication, with Metformin, a biguanide, to provide a synergistic approach to managing type 2 diabetes mellitus. Glimepiride stimulates the pancreas to release insulin, lowering blood glucose levels, while Metformin decreases glucose production by the liver and enhances insulin sensitivity in peripheral tissues. The PR (prolonged-release) formulation of Metformin allows for a gradual release of the drug into the bloodstream, leading to improved glycemic control with a lower incidence of gastrointestinal side effects compared to immediate-release formulations.
Recommended by specialists:
✅Endocrinologists – It is preferred to treat the disease associated with hormonal and metabolic disorders
✅General Physicians – It is preferred to treat the disease associated with routine Type 2 Diabetes Mellitus management.
✅Diabetologists: It is preferred to treat the disease associated with managing diabetes.
Key benefits of Metformin Hydrochloride Prolonged Release & Glimepiride Tablets IP – ASORIN M1 Tablets:
✅Synergistic Action: The combination of Glimepiride and Metformin targets diabetes management from two complementary mechanisms, leading to more effective control of blood glucose levels.
✅Prolonged Release: The PR formulation of Metformin allows for sustained release, promoting stable blood sugar levels throughout the day while minimising the gastrointestinal side effects often associated with immediate-release Metformin.
✅Lower Risk of Hypoglycemia: When used at appropriate doses, Glimepiride has a lower risk of causing hypoglycemia compared to other sulfonylureas, particularly in combination with Metformin.
INDICATIONS:
✅ Long-term diabetes management
✅Postprandial and fasting glucose levels
✅Type 2 diabetes mellitus
✅Insulin resistance T2DM
Related Products
Follow us on
Proin volutpat vitae libero at tincidunt. Maecenas sapien lectus, vehicula vel euismod sed, vulputate
10% off when you sign up
Proin volutpat vitae libero at tincidunt. Maecenas sapien lectus, vehicula vel euismod sed, vulputate
Fawn Incor Private Limited
Fawn Incor Private Limited is one of the fastest-growing and rapidly developing PCD Pharma Franchise Company in India. With proven expertise in the healthcare sector, we cater to the diverse needs of our customers by offering a wide range of general and specialty divisions, including Gynecology, Dermatology, Orthopedics, Neurology, Ophthalmology, Cardiac-Diabetic care, and PPIs.
USEFUL LINKS
Contact us
Panchkula (Admin Office)
Plot No 404, Basement, Industrial Area, Phase I, Panchkula (HR) 134113
Mumbai(Corporate Office)
3rd Floor, Tree House, Raghuvanshi Mills, Lower Parel (West), Mumbai – 400013 India
Netherlands (Overseas)
Fawn Inc. 217, Lichstraat, Eindhoven, Netherlands
+91-9888099264
+91 6280 986 280
+91-7814201203
info@fawnincor.com
Fawnincor@gmail.com
Copyright © Fawn Incor Pvt. Ltd. 2024. All Rights Reserved.
